Janus激酶抑制剂在皮肤病治疗中的应用前景

doi:10.35541/cjd.20190564

Abstract

Abstract: 【Abstract】 The JAK-STAT signaling pathway, composed of Janus kinase (JAK) and signal transducer and activator of transcription (STAT), is an important intracellular signaling pathway. It is involved in the occurrence of many inflammatory diseases. Blocking this pathway by JAK inhibitors has become an effective approach to the treatment of some diseases, such as rheumatoid arthritis and ulcerative colitis. However, JAK inhibitors have not been approved for the treatment of skin diseases at present. This review summarizes application prospects of JAK inhibitors in the treatment of skin diseases.

Key words: Janus kinases, Protein kinase inhibitors, Signal transduction, Skin diseases, Inflammation, Inflammatory dermatosis, Treatment outcome, Drug toxicity

Li Ming, Zhou Lihong, Li Linfeng. Prospects of Janus kinase inhibitors in the treatment of skin diseases[J]. Chinese Journal of Dermatology, 2020, 53(10): 845-848.doi:10.35541/cjd.20190564

References ［32］

［1］	Winthrop KL. The emerging safety profile of JAK inhibitors in rheumatic disease［J］. Nat Rev Rheumatol, 2017,13（4）:234⁃243. doi: 10.1038/nrrheum.2017.23.
［2］	Ciechanowicz P, Rakowska A, Sikora M, et al. JAK⁃inhibitors in dermatology: current evidence and future applications［J］. J Dermatolog Treat, 2019,30（7）:648⁃658. doi: 10.1080/09546634. 2018.1546043.
［3］	杨玉慧, 许秀丽, 张波. 治疗类风湿性关节炎新药托法替布［J］. 临床药物治疗杂志, 2018,16（12）:53⁃56,60. doi: 10.3969/j.issn.1672⁃3384.2018.12.013.
［4］	Morelli M, Scarponi C, Mercurio L, et al. Selective immunomodulation of inflammatory pathways in keratinocytes by the Janus kinase （JAK） inhibitor tofacitinib: implications for the employment of JAK⁃Targeting drugs in psoriasis［J］. J Immunol Res, 2018,2018:7897263. doi: 10.1155/2018/7897263.
［5］	Strober BE, Gottlieb AB, van de Kerkhof P, et al. Benefit⁃risk profile of tofacitinib in patients with moderate⁃to⁃severe chronic plaque psoriasis: pooled analysis across six clinical trials［J］. Br J Dermatol, 2019,180（1）:67⁃75. doi: 10.1111/bjd.17149.
［6］	Papp KA, Menter MA, Raman M, et al. A randomized phase 2b trial of baricitinib, an oral Janus kinase （JAK） 1/JAK2 inhibitor, in patients with moderate⁃to⁃severe psoriasis［J］. Br J Dermatol, 2016,174（6）:1266⁃1276. doi: 10.1111/bjd.14403.
［7］	Valenzuela F, Paul C, Mallbris L, et al. Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient⁃reported outcomes from a Phase 3 study［J］. J Eur Acad Dermatol Venereol, 2016,30（10）:1753⁃1759. doi: 10.1111/jdv.13702.
［8］	Ports WC, Khan S, Lan S, et al. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis［J］. Br J Dermatol, 2013,169（1）:137⁃145. doi: 10.1111/bjd.12266.
［9］	Papp KA, Bissonnette R, Gooderham M, et al. Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial［J］. BMC Dermatol, 2016,16（1）:15. doi: 10.1186/s12895⁃016⁃0051⁃4.
［10］	He H, Guttman⁃Yassky E. JAK inhibitors for atopic dermatitis: an update［J］. Am J Clin Dermatol, 2019,20（2）:181⁃192. doi: 10.1007/s40257⁃018⁃0413⁃2.
［11］	Levy LL, Urban J, King BA. Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate［J］. J Am Acad Dermatol, 2015,73（3）:395⁃399. doi: 10.1016/j.jaad.2015.06.045.
［12］	Guttman⁃Yassky E, Silverberg JI, Nemoto O, et al. Baricitinib in adult patients with moderate⁃to⁃severe atopic dermatitis: a phase 2 parallel, double⁃blinded, randomized placebo⁃controlled multiple⁃dose study［J］. J Am Acad Dermatol, 2019,80（4）:913⁃921.e9. doi: 10.1016/j.jaad.2018.01.018.
［13］	Bissonnette R, Papp KA, Poulin Y, et al. Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial［J］. Br J Dermatol, 2016,175（5）:902⁃911. doi: 10.1111/bjd.14871.
［14］	Wang Y, Li S, Li C. Perspectives of new advances in the pathogenesis of vitiligo: from oxidative stress to autoimmunity［J］. Med Sci Monit, 2019,25:1017⁃1023. doi: 10.12659/MSM. 914898.
［15］	Craiglow BG, King BA. Tofacitinib citrate for the treatment of vitiligo: a pathogenesis⁃directed therapy［J］. JAMA Dermatol, 2015,151（10）:1110⁃1112. doi: 10.1001/jamadermatol.2015.1520.
［16］	Kim SR, Heaton H, Liu LY, et al. Rapid repigmentation of vitiligo using tofacitinib plus low⁃dose, narrowband UV⁃B phototherapy［J］. JAMA Dermatol, 2018,154（3）:370⁃371. doi: 10.1001/jamadermatol.2017.5778.
［17］	Harris JE, Rashighi M, Nguyen N, et al. Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata （AA）［J］. J Am Acad Dermatol, 2016,74（2）:370⁃371. doi: 10.1016/j.jaad.2015.09.073.
［18］	Gianfaldoni S, Tchernev G, Wollina U, et al. Micro ⁃ focused phototherapy associated to janus kinase inhibitor: a promising valid therapeutic option for patients with localized vitiligo［J］. Open Access Maced J Med Sci, 2018,6（1）:46⁃48. doi: 10.3889/oamjms.2018.042.
［19］	Liu LY, Strassner JP, Refat MA, et al. Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure［J］. J Am Acad Dermatol, 2017,77（4）:675⁃682.e1. doi: 10.1016/j.jaad.2017.05.043.
［20］	Rothstein B, Joshipura D, Saraiya A, et al. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib［J］. J Am Acad Dermatol, 2017,76（6）:1054⁃1060.e1. doi: 10.1016/j.jaad. 2017.02.049.
［21］	Joshipura D, Alomran A, Zancanaro P, et al. Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: a 32⁃week open⁃label extension study with optional narrow⁃band ultraviolet B［J］. J Am Acad Dermatol, 2018,78（6）:1205⁃1207.e1. doi: 10. 1016/j.jaad.2018.02.023.
［22］	Xing L, Dai Z, Jabbari A, et al. Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition［J］. Nat Med, 2014,20（9）:1043⁃1049. doi: 10.1038/nm.3645.
［23］	Kennedy Crispin M, Ko JM, Craiglow BG, et al. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata［J］. JCI Insight, 2016,1（15）:e89776. doi: 10.1172/jci.insight.89776.
［24］	Liu LY, King BA. Ruxolitinib for the treatment of severe alopecia areata［J］. J Am Acad Dermatol, 2019,80（2）:566⁃568. doi: 10. 1016/j.jaad.2018.08.040.
［25］	Almutairi N, Nour TM, Hussain NH. Janus kinase inhibitors for the treatment of severe alopecia areata: an open⁃label comparative study［J］. Dermatology, 2019,235（2）:130⁃136. doi: 10.1159/000494613.
［26］	余丽娟, 吕中法. JAK抑制剂治疗斑秃的研究进展［J］. 中华皮肤科杂志, 2019,52（5）:343⁃346. doi: 10.3760/cma.j.issn.0412⁃4030.2019.05.014.
［27］	Liu LY, Craiglow BG, King BA. Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: a pilot study of 10 patients［J］. J Am Acad Dermatol, 2018,78（2）:403⁃404.e1. doi: 10.1016/j.jaad.2017.10.043.
［28］	Putterman E, Castelo⁃Soccio L. Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis［J］. J Am Acad Dermatol, 2018,78（6）:1207⁃1209.e1. doi: 10.1016/j.jaad.2018.02.031.
［29］	Winthrop KL, Lebwohl M, Cohen AD, et al. Herpes zoster in psoriasis patients treated with tofacitinib［J］. J Am Acad Dermatol, 2017,77（2）:302⁃309. doi: 10.1016/j.jaad.2017.03.023.
［30］	Curtis JR, Lee EB, Martin G, et al. Analysis of non⁃melanoma skin cancer across the tofacitinib rheumatoid arthritis clinical programme［J］. Clin Exp Rheumatol, 2017,35（4）:614⁃622.
［31］	Xie W, Huang Y, Xiao S, et al. Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta⁃analysis of randomised controlled trials［J］. Ann Rheum Dis, 2019,78（8）:1048⁃1054. doi: 10.1136/annrheumdis⁃2018⁃214846.
［32］	Kurtzman DJ, Wright NA, Lin J, et al. Tofacitinib citrate for refractory cutaneous dermatomyositis: an alternative treatment［J］. JAMA Dermatol, 2016,152（8）:944⁃945. doi: 10.1001/jamadermatol. 2016.0866.

[1]	Wei Jin, Zang Dongjie, Zeng Sanwu, Jiang Jing, Lun Wenhui. Mutation analysis of the KRT5 gene in a Chinese pedigree with Dowling-Degos disease [J]. Chinese Journal of Dermatology, 2022, 55(8): 703-705.
[2]	Jin Liang, Liu Ling. Treatment of some genodermatoses [J]. Chinese Journal of Dermatology, 2022, 55(8): 735-739.
[3]	Xu Zhe. Some thoughts on hereditary dermatoses [J]. Chinese Journal of Dermatology, 2022, 55(8): 651-652.
[4]	Gao Zirui, Zhao Pei, Dou Yuanqing, Liu Ping, Zhang Jianzhong. Efficacy and safety of dupilumab in the treatment of adult prurigo nodularis [J]. Chinese Journal of Dermatology, 2022, 55(7): 562-565.
[5]	Liu Yixuan, Jiang Peiyu, Liu Yunyi, Zhang Jiawen, Tao Meng, Li Min, Xu Yang. Mechanism of neurogenic inflammation and botulinum toxin treatment in rosacea [J]. Chinese Journal of Dermatology, 2022, 55(6): 552-554.
[6]	Working Group for Atopic Dermatitis, Chinese Society of Dermatology, Working Group for Children′s Diseases, Chinese Society of Dermatology. Treatment of atopic dermatitis with dupilumab: an expert consensus [J]. Chinese Journal of Dermatology, 2022, 55(6): 465-470.
[7]	Committee on Autoimmune Diseases, China Dermatologist Association. Cyclosporine in the treatment of immune-related skin diseases: an expert proposal [J]. Chinese Journal of Dermatology, 2022, 55(6): 471-479.
[8]	Huang Xin, Chen Xiaoyun, Li Yaping, Liang Xingkun, Zhang Guiying, Zhou Ying, Zhan Yi, Luo Shuaihantian, Liao Jieyue, Xiao Rong, Long Hai. Efficacy and safety of dupilumab in the treatment of 123 cases of atopic dermatitis [J]. Chinese Journal of Dermatology, 2022, 55(6): 486-493.
[9]	Li Danqi, Lou Yuchen, Tao Juan. Application of high-dose intravenous immunoglobulin therapy in severe dermatoses [J]. Chinese Journal of Dermatology, 2022, 55(5): 455-459.
[10]	Shan Ying, Zuo Yagang. Correlation between autoimmune bullous diseases and psoriasis [J]. Chinese Journal of Dermatology, 2022, 55(5): 452-455.
[11]	Hu Yebei, Song Xiuzu. Tranexamic acid for the treatment of melasma [J]. Chinese Journal of Dermatology, 2022, 55(5): 460-462.
[12]	Li Wei, Yin Huibin. Heterogeneity across skin sites in atopic dermatitis [J]. Chinese Journal of Dermatology, 2022, 55(4): 349-352.
[13]	Li Yan, Li Ming, Xu Wei, Li Linfeng. Calcium-based antimicrobial peptide compounds cooling gel for the treatment of atopic dermatitis: a randomized, double-blind controlled clinical study [J]. Chinese Journal of Dermatology, 2022, 55(4): 345-348.
[14]	Liu Bo, Song Xiaoting, Liao Shuanglu, Yu Miao, Luan Tingting, Li Ruoyu, Zhao Zuotao. Efficacy and safety of baricitinib in the treatment of moderate-to-severe atopic dermatitis: a clinical observation [J]. Chinese Journal of Dermatology, 2022, 55(4): 304-307.
[15]	Liu Bo, Song Xiaoting, Li Ruoyu, Zhao Zuotao. Clinical efficacy and safety of dupilumab in the treatment of atopic dermatitis [J]. Chinese Journal of Dermatology, 2022, 55(4): 295-298.

Prospects of Janus kinase inhibitors in the treatment of skin diseases

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［32］

Related Articles 15

Metrics

Comments

Recommended 10